glp-1 breast cancer Too Good to Be True?' GLP-1s and Survival A trio of large observational
Description
In 2022, just over 7 million prescriptions for GLP-1s were written for adults without diabetes, up from 1.3 million in 2019
You could continue the SU, but you decide to stop it because the additive effect of these medications increases the risk of hypoglycemia
Elevated levels of triglycerides and free fatty acids in circulation are major factors driving lipid accumulation in the liver, leading to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis
This is an unprecedented global health crisis, which imposes a considerable burden on health systems
Comparative Risk: In patients with Type 2 Diabetes, GLP-1 RA use was associated with a 7% lower cancer incidence compared with DPP4 inhibitors
